Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025 episode artwork

EPISODE · Nov 26, 2025 · 4 MIN

Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025

from Medical Digest & Congress Report · host Medical Congress News

Dr. Evan A Stein shares his insights on the emerging opportunities for managing cardiometabolic syndrome at AHA Scientific Sessions 2025.Video: https://medicaldigest.org/scientific-contents/interview:long-term-efficacy-and-safety-lerodalcibep-open-label-72-week-extension-study-subjects-previously-inclisiran-or-lerodalcibep-liberate-vi-trial

Episode metadata supplied by the publisher feed · Published Nov 26, 2025

Embed this episode

Ready to play

Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025

0:00 4:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 4 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on November 26, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!